Helsinn announces publication of anamorelin ROMANA 1 and ROMANA 2 Phase III studies in The Lancet Oncology

Lugano, Switzerland, 23 February, 2016 – Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that on February 19th the journal, The Lancet Oncology, published the results from the pivotal ROMANA Phase III trials assessing efficacy and safety of the ghrelin receptor agonist anamorelin in patients with Cancer Anorexia-Cachexia in non-small cell lung cancer (NSCLC). The lead author was Dr. Jennifer Temel, from the Massachusetts General Hospital in Boston (USA).

 

The paper, “Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results fromtwo randomised, double-blind, phase 3 trials”, can be accessed here: [www.thelancet.com/journals/lanonc/onlinefirst] and an executive summary of the Lancet Oncology article is available below.

 

Cancer Anorexia-Cachexia is a frequent condition in patients with advanced cancer, in particular in those with lung cancer. A combination of reduced food intake and altered metabolism leads to loss of lean body mass and body weight in patients affected by this condition. There are few therapeutic options and no standard of care for the management of Cancer Anorexia-Cachexia. Despite the fact that some of the currently available drugs can improve patient’s appetite or increase body weight, none can substantially affect lean body mass.

Related Articles